Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page’s revision metadata was updated from v3.5.3 to v3.5.4, indicating an internal platform update. There is no indication that the study content or user-facing information was altered.
    Difference
    0.0%
    Check dated 2026-05-16T07:36:43.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    The page’s displayed revision/version number has been updated from **v3.5.2** to **v3.5.3**. This reflects a site or interface release rather than a change to the clinical trial information.
    Difference
    0.0%
    Check dated 2026-04-24T05:57:58.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:34:50.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Padova, Italy is added and Padua, Italy is removed from the Italy study locations.
    Difference
    0.0%
    Check dated 2026-04-09T21:35:44.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Naples, Italy was added to the locations list and Napoli, Italy was removed from the locations list.
    Difference
    0.0%
    Check dated 2026-03-26T11:29:10.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T04:21:03.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.